

Market Round-up

V31 – 11th January, 2019

General Market News:

- **Takeda's** takeover of **Shire** has completed
[LINK](#)
- **Sanofi's Cablivi** gets positive results for rare blood clotting disorder
[LINK](#)
- **Statins** may help treat serious mental illness
[LINK](#)
- **Mylan** acquires ARV drugs manufacturing plant in South Africa
[LINK](#)
- Call for Ireland to be in top quartile for speed of access to new medicines from **Brid O'Connell**, CEO with **Guaranteed Irish**
[LINK](#)

NCPE Drug Updates

- No updates this week.

Drug Approvals/Filings:

- **NICE** has approved **Pfizer's** oral drug **Xeljanz** (tofacitinib) for adults with moderate to severe active ulcerative colitis.
[LINK](#)
- **NICE** has rejected **Novartis'** migraine drug **Aimovig** saying it's too costly for NHS
[LINK](#)
- FDA approves **Teva's** integrated digital rescue inhaler
[LINK](#)
- Billed as potential blockbuster, **Novartis'** sickle cell drug **crizanlizumab** scores FDA's breakthrough therapy status
[LINK](#)
- **Amgen's** osteoporosis bone-forming drug **Evenity** (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month.
[LINK](#)

Further Reading:

- **M&A, IPOs** and VC raises: Biotech and medtech executives look to their crystal balls for 2019
[LINK](#)
- **Novartis** puts **AI** on the job to help reps say the right things to the right doctors
[LINK](#)
- Editorial: **The Irish Times** view on health services: allaying public concern
[LINK](#)